title: Theophylline treatment may adversely affect the anoxia-induced erythropoietic response without suppressing erythropoietin production.
abstract: OBJECTIVE
  To investigate the influence of theophylline on erythropoiesis in chronic obstructive pulmonary disease (COPD) and explore the potential underlying mechanisms.
  
  
  METHODS
  We evaluated the haematological parameters and erythropoietin (EPO) values in 38 COPD patients, 18 of which had been treated with theophylline (8 mg/kg daily) for at least 1 year, and the other 20 had never received this drug; 38 sex- and age-matched healthy volunteers served as controls. We further studied the development of BFU-E (bursts forming units of erythrocyte precursors) -derived colonies in semisolid methylcellulose cultures in blood samples from 7 patients randomly selected from both groups. In addition, we studied the effects of theophylline on the erythroid cell development by adding this agent to erythroid cell cultures from 6 healthy volunteers at various concentrations.
  
  
  RESULTS
  Haemoglobin values were found to be significantly lower in COPD patients treated with theophylline than in those untreated ( P<0.05). Both groups of patients exhibited significantly higher haemoglobin values than normal subjects ( P<0.01 and P<0.001 for treated and untreated patients, respectively). Serum EPO levels did not differ among the three studied groups. Unlike untreated patients and controls, the serum of the theophylline-treated patients produced a significant growth inhibition of erythroid bursts ( P<0.05); the in vitro use of theophylline showed a concentration-dependent inhibition ( P<0.001).
  
  
  CONCLUSIONS
  Our findings confirm the decrease of red cell production, which occurs following administration of theophylline, exclude the possibility of decreased EPO synthesis and suggest a direct inhibitory action of theophylline on erythropoiesis.
authors.affiliation: Laboratory of Haematology, Athens General Hospital "G. Gennimatas", Athens, Greece.
authors.forename: Argirios E
authors.initials: AE
authors.lastname: Tsantes
authors.forename: Stergios T
authors.initials: ST
authors.lastname: Tassiopoulos
authors.forename: Stefanos I
authors.initials: SI
authors.lastname: Papadhimitriou
authors.forename: Stefanos
authors.initials: S
authors.lastname: Bonovas
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Poulakis
authors.forename: Athina
authors.initials: A
authors.lastname: Vlachou
authors.forename: Kalitsa
authors.initials: K
authors.lastname: Filioussi
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Loukopoulos
mesh_terms: D000368:Aged; D001993:Bronchodilator Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000378:metabolism*; D013806:Theophylline / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D001993:Bronchodilator Agents; D004921:Erythropoietin; D013806:Theophylline